News

Vivani's board chair, director back implant maker with $5.1M placement

What's the deal? Vivani MedicalDealroom has a profile for this one. Try Dealroom → (Nasdaq: VANI) has raised roughly $5.1 million in a private placement, selling 5,049,506 shares at $1.01 each to Gregg Williams, chairman of its board, and board member Aaron MendelsohnDealroom has a profile for this one. Try Dealroom →. The at-the-market deal, agreed November 15, is expected to close around November 23.

What does Vivani do? The clinical-stage biopharmaceutical company develops miniature, long-acting drug implants using its NanoPortal platform. It is building a portfolio of GLP-1 implants for obesity and type 2 diabetes, designed for once- or twice-yearly dosing rather than daily pills or weekly injections.

Why now? The raise follows November 12 top-line results from SLIM-1, the first-in-human Phase 1 trial of NPM-139, Vivani's semaglutide implant. The results support advancing the candidate toward a Phase 2 dose-ranging weight maintenance trial planned for 2027.

The trial data: SLIM-1 ran four weeks in 20 overweight or obese participants, with 10 on low-dose NPM-139 and 10 on the starting dose of Wegovy. No NPM-139 participants had treatment-related adverse events, versus five of 10 in the Wegovy group, all gastrointestinal. No serious adverse events were reported.

What's the money for? Vivani will use the net proceeds to fund research and clinical development of NPM-139 and other candidates, plus working capital. With existing cash, the company expects the funds to support operations into the third quarter of 2027.

The signal: The round extends Vivani's pattern of leaning on share sales — including deals in 2025 and January 2026 — to finance development. With the board itself buying in after positive trial data and a Novo Nordisk evaluation agreement in hand, insiders are signalling confidence as the implant moves toward a larger study.

Read more: smb.magnoliastatelive.com

Image credit: "Miniaturized implantable systems for physiological monitoring" by oakridgelabnews, licensed under CC BY 2.0

More top stories